share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Lurker Nancy

SEC ·  Jul 13 05:07
Summary by Futu AI
EyePoint Pharmaceuticals, Inc. (EYPT) has reported a completed transaction involving Executive Vice Chair Nancy Lurker. On July 10, 2024, Lurker acquired 11,111 shares of EyePoint Pharmaceuticals' common stock at no cost, as part of an exercise or conversion of a derivative security. Following this transaction, Lurker directly holds a total of 94,462 shares. Additionally, there is an indirect holding of 126,889 shares by a family trust associated with Lurker. The transaction reflects a strengthening of Lurker's investment in the company and may be of interest to current and potential investors.
EyePoint Pharmaceuticals, Inc. (EYPT) has reported a completed transaction involving Executive Vice Chair Nancy Lurker. On July 10, 2024, Lurker acquired 11,111 shares of EyePoint Pharmaceuticals' common stock at no cost, as part of an exercise or conversion of a derivative security. Following this transaction, Lurker directly holds a total of 94,462 shares. Additionally, there is an indirect holding of 126,889 shares by a family trust associated with Lurker. The transaction reflects a strengthening of Lurker's investment in the company and may be of interest to current and potential investors.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.